Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody

Ussama M. Abdel-Motal, Kim Wigglesworth, Uri Galili

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Anti-Gal constitutes ∼1% of circulating IgG in humans and interacts specifically with α-gal epitopes. We reported previously that expression of α-gal epitopes on HIV gp120 and influenza virus vaccines increases immunogenicity by ∼100-fold. We hypothesize that immunogenicity of any microbial vaccine can be markedly increased by linked α-gal epitopes due to in vivo formation of immune complexes with anti-Gal and the effective internalization of such immune complexes by APC, via Fc/FcγR interaction. The increased transport to lymph nodes and processing of anti-Gal complexed vaccines internalized by APC, results in effective activation of vaccine specific CD4+ and CD8+ T cells, and high cellular and humoral immune response. This universal mechanism for anti-Gal mediated increased immunogenicity is demonstrated in α1,3galactosyltransferase knockout mice with ovalbumin as a model vaccine.

Original languageEnglish
Pages (from-to)3072-3082
Number of pages11
JournalVaccine
Volume27
Issue number23
DOIs
Publication statusPublished - 18 May 2009
Externally publishedYes

Fingerprint

antigen-antibody complex
Antigen-Antibody Complex
Anti-Idiotypic Antibodies
Vaccines
immune response
vaccines
Epitopes
antibodies
epitopes
HIV Envelope Protein gp120
Influenza Vaccines
Ovalbumin
Humoral Immunity
Knockout Mice
Cellular Immunity
ovalbumin
Orthomyxoviridae
humoral immunity
Immunoglobulin G
cell-mediated immunity

Keywords

  • α-Gal glycolipids
  • Anti-Gal antibody
  • APC
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody. / Abdel-Motal, Ussama M.; Wigglesworth, Kim; Galili, Uri.

In: Vaccine, Vol. 27, No. 23, 18.05.2009, p. 3072-3082.

Research output: Contribution to journalArticle

@article{b150e0ef61984470b30c2b47fedeb44d,
title = "Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody",
abstract = "Anti-Gal constitutes ∼1{\%} of circulating IgG in humans and interacts specifically with α-gal epitopes. We reported previously that expression of α-gal epitopes on HIV gp120 and influenza virus vaccines increases immunogenicity by ∼100-fold. We hypothesize that immunogenicity of any microbial vaccine can be markedly increased by linked α-gal epitopes due to in vivo formation of immune complexes with anti-Gal and the effective internalization of such immune complexes by APC, via Fc/FcγR interaction. The increased transport to lymph nodes and processing of anti-Gal complexed vaccines internalized by APC, results in effective activation of vaccine specific CD4+ and CD8+ T cells, and high cellular and humoral immune response. This universal mechanism for anti-Gal mediated increased immunogenicity is demonstrated in α1,3galactosyltransferase knockout mice with ovalbumin as a model vaccine.",
keywords = "α-Gal glycolipids, Anti-Gal antibody, APC, Vaccine",
author = "Abdel-Motal, {Ussama M.} and Kim Wigglesworth and Uri Galili",
year = "2009",
month = "5",
day = "18",
doi = "10.1016/j.vaccine.2009.03.019",
language = "English",
volume = "27",
pages = "3072--3082",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "23",

}

TY - JOUR

T1 - Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody

AU - Abdel-Motal, Ussama M.

AU - Wigglesworth, Kim

AU - Galili, Uri

PY - 2009/5/18

Y1 - 2009/5/18

N2 - Anti-Gal constitutes ∼1% of circulating IgG in humans and interacts specifically with α-gal epitopes. We reported previously that expression of α-gal epitopes on HIV gp120 and influenza virus vaccines increases immunogenicity by ∼100-fold. We hypothesize that immunogenicity of any microbial vaccine can be markedly increased by linked α-gal epitopes due to in vivo formation of immune complexes with anti-Gal and the effective internalization of such immune complexes by APC, via Fc/FcγR interaction. The increased transport to lymph nodes and processing of anti-Gal complexed vaccines internalized by APC, results in effective activation of vaccine specific CD4+ and CD8+ T cells, and high cellular and humoral immune response. This universal mechanism for anti-Gal mediated increased immunogenicity is demonstrated in α1,3galactosyltransferase knockout mice with ovalbumin as a model vaccine.

AB - Anti-Gal constitutes ∼1% of circulating IgG in humans and interacts specifically with α-gal epitopes. We reported previously that expression of α-gal epitopes on HIV gp120 and influenza virus vaccines increases immunogenicity by ∼100-fold. We hypothesize that immunogenicity of any microbial vaccine can be markedly increased by linked α-gal epitopes due to in vivo formation of immune complexes with anti-Gal and the effective internalization of such immune complexes by APC, via Fc/FcγR interaction. The increased transport to lymph nodes and processing of anti-Gal complexed vaccines internalized by APC, results in effective activation of vaccine specific CD4+ and CD8+ T cells, and high cellular and humoral immune response. This universal mechanism for anti-Gal mediated increased immunogenicity is demonstrated in α1,3galactosyltransferase knockout mice with ovalbumin as a model vaccine.

KW - α-Gal glycolipids

KW - Anti-Gal antibody

KW - APC

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=67349093586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349093586&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.03.019

DO - 10.1016/j.vaccine.2009.03.019

M3 - Article

C2 - 19428921

AN - SCOPUS:67349093586

VL - 27

SP - 3072

EP - 3082

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 23

ER -